Topics covered: The FDA Clamp-Down, The changing Pharmaceutical Business Model, Targeted Therapies in Oncology, Supplying unmet medical needs, Stem cell preservation, Phase III Trials, Pharmaceutical and Biotech partnerships, Oncology and Acute care, New uses for stalled drugs, Intracellular Signaling Pathways, Growing new blood vessels, Antisense Technology
Topics covered: Video Games, Therapeutic indications, The tanker segment, The LPG market, The dry bulk segment, The antiviral space, Sluggish semi cap momentum, RNAi and antisense technology, Obesity, Metabolic disease, Memory spending, Inventory levels, Inflammation and pain, Healthcare information technology, DRAM growth, Combination compounds, CNS disease indications, Anti-aging categories, Aesthetic laser companies
Topics covered: Volatility, Small and mid-cap investing, Sell rules to protect capital, Robust growth relative to large cap companies, Not incurring large losses, Mutual funds, Mid-cap management teams, Laddered bond strategy, GARP investing, Diversified asset allocation, Computer screening, Analysis of investment professionals
Topics covered: Student housing, Slowly rising rates of return, Slowing RevPAR and profit growth, Single-family housing market downturn, Rental apartments, REIT stock valuation levels, Real estate stocks, Market value of real estate assets, Industrial REITs, Deceleration phase of hotels, Commercial real estate assets
Topics covered: Volumes, US and Mexican brewers, Strong growth in most non-carbonated segments, Special situations, Price increases, Incremental volume and profit growth opportunities in non-carbs, High commodity costs of beer, Diversified product mixes, Declining soft drink volumes, Cost inflation in aluminum and corn syrup, Consumers drinking less domestic beer, Beverage companies performance
